VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 32,826 shares, a decline of 62.6% from the February 12th total of 87,870 shares. Based on an average trading volume of 94,910 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.3% of the company’s shares are sold short. Currently, 1.3% of the company’s shares are sold short. Based on an average trading volume of 94,910 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is owned by institutional investors.

VivoSim Labs Stock Up 2.1%

Shares of VivoSim Labs stock opened at $1.94 on Thursday. The business has a 50 day moving average of $2.03 and a 200 day moving average of $2.38. VivoSim Labs has a 52 week low of $1.41 and a 52 week high of $5.52. The company has a market cap of $5.06 million, a PE ratio of -0.62 and a beta of 1.25.

VivoSim Labs (NASDAQ:VIVS) last released its quarterly earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share for the quarter. The company had revenue of $0.03 million during the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.